Skip to main content
Top
Published in: International Journal of Hematology 5/2016

01-05-2016 | Images in Hematology

Signet ring cell “lymphoma”: mimicking the appearance of signet ring cell carcinoma

Authors: Kazuya Sakai, Naoya Yamasaki, Kenji Notohara, Yasunori Ueda

Published in: International Journal of Hematology | Issue 5/2016

Login to get access

Excerpt

A 70-year-old man presented with a 1-month history of intermittent epigastric pain. Emergency upper endoscopy revealed acute gastric ulcer. Abnormal findings of blood analysis included anemia (hemoglobin level: 8.1 g/dL), thrombocytopenia (platelet count: 29000/μL), high levels of lactase dehydrogenase (LDH: 983 IU/L), hypercalcemia (11.8 mg/dL) and renal failure (serum creatinine: 2.8 mg/dL). 18-Fluoro-2-deoxyglucose (FDG) positron emission tomography scan showed marked FDG uptake in the angular incisure, and in the systemic lymph nodes and bones (Fig. 1a, b). A second upper endoscopy biopsy was performed to obtain samples for pathological analysis, which showed diffuse infiltration by a “signet-ring”-like tumor (Fig. 2a, c). These tumor cells had round and large cytoplasmic vacuoles, and compressed atypical nuclei in a crescent shape. The initial impression was signet ring cell carcinoma, primary gastric tumor and its metastasis. Immunohistochemical staining, however, demonstrated that the tumor cells were positive for CD10, CD 20, bcl-2, and MUM-1, leading to a diagnosis of diffuse large B cell lymphoma (Fig. 2d). The cytoplasmic vacuoles were negative for PAS (periodic acid-Schiff) staining. The same tumor cells were also found in bone marrow biopsy specimen. Subsequently he received systemic chemotherapy (R-THP-COP therapy; combinations of rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisolone), but died from primary disease progression after 3 months.
Literature
Metadata
Title
Signet ring cell “lymphoma”: mimicking the appearance of signet ring cell carcinoma
Authors
Kazuya Sakai
Naoya Yamasaki
Kenji Notohara
Yasunori Ueda
Publication date
01-05-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-1983-5

Other articles of this Issue 5/2016

International Journal of Hematology 5/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine